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Background: The NHS Bowel Cancer Screening Programme in England offers biennial guaiac faecal occult blood testing (gFOBt).
There is a socioeconomic gradient in participation and socioeconomically disadvantaged groups have worse colorectal cancer
survival than more advantaged groups. We compared the effectiveness and cost of an enhanced reminder letter with the usual
reminder letter on overall uptake of gFOBt and the socioeconomic gradient in uptake.
Methods: We enhanced the usual reminder by including a heading ‘A reminder to you’ and a short paragraph restating the offer
of screening in simple language. We undertook a cluster-randomised trial of all 168 480 individuals who were due to receive a
reminder over 20 days in 2013. Randomisation was based on the day of invitation. Blinding of individuals was not possible, but the
possibility of bias was minimal owing to the lack of direct contact with participants. The enhanced reminder was sent to 78 067
individuals and 90 413 received the usual reminder. The primary outcome was the proportion of people adequately screened and
its variation by quintile of Index of Multiple Deprivation. Data were analysed by logistic regression with conservative variance
estimates to take account of cluster randomisation.
Results: There was a small but statistically significant (P¼ 0.001) increase in participation with the enhanced reminder (25.8% vs
25.1%). There was significant (P¼ 0.005) heterogeneity of the effect by socioeconomic status with an 11% increase in the odds of
participation in the most deprived quintile (from 13.3 to 14.1%) and no increase in the least deprived. We estimated that
implementing the enhanced reminder nationally could result in up to 80 more people with high or intermediate risk colorectal
adenomas and up to 30 more cancers detected each year if it were implemented nationally. The intervention incurred a small one-
off cost of d78 000 to modify the reminder letter.
Conclusions: The enhanced reminder increases overall uptake and reduces the socioeconomic gradient in bowel cancer
screening participation at little additional cost.
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Colorectal cancer is a major public health problem internationally
and in the United Kingdom, where it is the third most common
cancer and the second leading cause of cancer death. (Ferlay et al,
2012; Cancer Research UK, 2014) Randomised trials have shown
that screening using guaiac faecal occult blood testing (gFOBt)
significantly reduces mortality from colorectal cancer. (Hewitson
et al, 2008) In 2006 the English NHS Bowel Cancer Screening
Programme (BCSP) introduced two-yearly gFOBT screening and
now offers it to all individuals aged 60–74 years.
For population cancer screening to achieve its intended public
health impact, high levels of participation are necessary. National
variations in screening uptake, examined between 2006 and 2009
found that uptake overall was 54% and that this varied from 61% in
the least deprived to 35% in the most deprived areas of the country.
(von Wagner et al, 2011) The stepwise relationship between
socioeconomic group and health whereby more socioeconomically
advantaged individuals have better health and better access to
health care is well known. (Graham, 2004) The costs of inequalities
are therefore borne not only by those at the bottom of the
socioeconomic hierarchy but at every level. Interventions that
target the most disadvantaged subgroups only, or which aim to
narrow the gap between the most and least disadvantaged,
underestimate the pervasive effect across the socioeconomic
hierarchy and exclude those in need in the intermediate socio-
economic groups.
Participants with a positive gFOBt result are invited for further
investigation (usually colonoscopy). Fortunately, the low uptake
and striking socioeconomic gradients are not seen in attendance at
colonoscopy. Overall colonoscopy uptake is 83% with little
variation between socially advantaged and disadvantaged areas
(86–80%). (Morris et al, 2012) The high follow-up and low
socioeconomic gradient in uptake of colonoscopy indicates that
addressing the gFOBt uptake gradient should improve subsequent
uptake of effective treatment and therefore contribute to reducing
inequalities in survival. (Coleman et al, 2004).
In order to address the UK Government’s commitment to
reduce health inequalities, (Health, 2012) we undertook the
ASCEND-randomised controlled trials research programme. In
ASCEND we designed four interventions aimed at reducing the
socioeconomic gradient in bowel screening participation without
compromising uptake overall. The interventions were: a simplified
version of the information leaflet aimed at individuals with low
literacy or numeracy skills; a narrative information leaflet
including experiences of people who had participated in the BCSP;
general practitioner endorsement (GPE) of the invitation to
participate (80% of GP practices nationally agreed to endorse the
programme using the statement ‘your GP practice, name of
practice¸ supports the Bowel Cancer Screening Programme’ on
invitation letters); and an enhanced reminder letter (ER), replacing
the usual reminder sent to those who had not returned a kit within
4 weeks.
The summary results of the four national cluster-randomised
controlled trials (RCTs) of these interventions are provided
elsewhere. (Wardle et al, 2016) In this paper, we report details of
the impact of the national cluster-RCT of the enhanced reminder
on the socioeconomic gradient in BCSP uptake and its cost.
MATERIALS AND METHODS
Intervention. The value of sending reminders to improve screen-
ing uptake is well established (Camilloni et al, 2013) and all
individuals who are sent a bowel cancer screening kit as part of the
BCSP are sent a reminder letter if the kit is not returned within
4 weeks. Research on breast screening attendance suggests that
reminders maybe helpful in increasing uptake in low-income
women, (Chambers et al, 2014) particularly if the content of the
reminder addresses barriers to screening participation, which are
known to be socially graded. Evidence has demonstrated that low
awareness of bowel cancer is significantly more prevalent among
more deprived groups and that individuals from lower socio-
economic groups tend to perceive the barriers to screening to be
higher and the benefits of screening to be lower than high
socioeconomic groups. (Power et al, 2011; Whitaker et al, 2011)
One particular barrier to screening that has been extensively
studied and found to be an important predictor of colorectal cancer
screening uptake is perceived risk (Vernon, 1997; Vernon et al,
2001; Robb et al, 2004). We therefore developed an enhanced
reminder letter, which aimed to target low awareness of bowel
cancer and, in addition, specifically addressed inaccurate risk
perceptions. Increasing age is a risk factor and pertinent
characteristic of all screening invitees, regardless of their socio-
economic group and one that could be simply and directly stated.
We designed the enhanced reminder letter in collaboration with
the Health & Social Care Information Centre (HSCIC) to ensure
that the enhancement we developed would fit into the usual letter
without disrupting the format and thus without incurring any
additional costs to BCSP. We also obtained feedback from focus
group participants who had been convened to explore reasons for
non-uptake of bowel cancer screening. (Palmer et al, 2014) The
final version of the enhanced reminder included two additions to
the usual letter: a banner reading ‘A reminder to you’ at the start of
the letter and a brief restatement of the screening offer at the end of
the letter.
The control intervention was the usual reminder letter. The text
of both reminder letters is given in the web appendix.
(Supplementary files 1 and 2).
Randomisation and blinding. The study was carried out within
the routine activity of the BCSP. The BCSP in England is organised
within five regional hubs (Midlands and Northwest; Southern;
London; Northeast; and Eastern), all of which participated in this
trial. The intervention period of this study overlapped with our
trial of GPE of the offer of screening, so a proportion of individuals
were in both trials (see results below).
The invitation and reminder system of the Programme did not
permit randomisation of individual invitees. Instead, we rando-
mised days within hubs. That is, for a given date within a given
hub, all individuals who were due to be sent a reminder on that
date were randomised to the same trial arm, either the usual
reminder or enhanced reminder.
Blinding of individuals was not possible, but the possibility of
biasing participation was minimal owing to the lack of direct
contact with participants. Individuals were unaware of a compara-
tor condition unless a member of their household received a
reminder letter during the study period that contained different
information materials. Hubs however were effectively ‘blind’ to the
randomisation schedule, which was sent only to HSCIC. To assure
quality, Hubs reported back to the Trial Office whether the
intervention was included and this was checked against the
randomisation schedule by the research team.
Outcome measures and costs. The outcome measure (adequately
screened) was defined as the return of a gFOBt kit within 18 weeks
of the initial invitation that led to a ‘definitive’ test result of either
‘normal’ (i.e., no further investigation required) or ‘abnormal’
(i.e., requiring referral for further testing, usually colonoscopy) by
the date of data extraction. The 18-week time limit coincided with
the date on which the BCSP closes a screening episode to a non-
responder. The primary analysis addressed heterogeneity of the
effect of the enhanced reminder by socioeconomic status quintile.
Socioeconomic status was measured using the Index of Multiple
Deprivation (IMD) 2010 score associated with each individual’s
home address (Department for Communities and Local
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Government, 2011) IMD, a well validated marker of socio-
economic status, comprises 38 separate indicators, organised
across seven distinct domains (Income, Employment, Health and
Disability, Education Skills and Training, Barriers to Housing and
Other Services, Crime and Living Environment). These are
combined, using appropriate weights, to calculate the IMD for
every Lower Layer Super Output Area (LSOA) in England. Each
LSOA covers B1500 individuals. Each individual’s postcode was
linked to the relevant LSOA. The IMD can be used to rank every
LSOA in England according to their relative level of deprivation.
IMD was classified in five categories based on national quintiles,
(Wardle et al, 2016) with 1 representing the least deprived
and 5 the most deprived. In addition we estimated the overall effect
of the enhanced reminder intervention on participation rates.
We calculated the costs of modifying the BCSP IT system to
incorporate the enhanced reminder. This was based on the actual
cost charged to the study to modify the reminder letter.
Statistical considerations. Data were analysed by logistic regres-
sion with conservative variance estimates to take account of
randomisation by hub-day clusters. (Huber, 1967; White, 1980)
including interaction tests for heterogeneity of effect by IMD
quintile. We further adjusted for age, sex, hub and screening
episode type (first ever screening episode, prevalent episode in
previous non-participant or incident episode in previous partici-
pant). In formal testing for heterogeneity of effects of age, sex, hub
and screening episode type by socioeconomic status, we used the
continuous IMD score to increase statistical power.
We calculated average marginal effects (which give the effect on
absolute percentage uptake adjusted for other factors) and used
these to predict the impact of the enhanced reminder on the
detection of colorectal adenomas and cancer in the NHS BCSP.
Sample size was calculated using the method of Brentnall et al,
(2012) to give 90% power to detect as significant at the 5% level a
heterogeneity of the effect of the intervention by IMD quintile such
that the absolute increase in participation in the most deprived
quintile was 5 percentage points and the increase in the least
deprived was 1 percentage point. This indicated that 46 000
individuals would be required. With B1500 reminders sent per
hub per working day, this would have required 31 hub-day clusters.
To take account of the additional variation generated by the cluster
randomisation, we randomised 100 hub-days, the 20 working days
from Monday 8th July 2013 to Friday 2nd August 2013, in each of
the five hubs. Owing to a protocol deviation, data from one hub on
one day (8th July) could not be used. This gave a total of 99
randomisation units and 168 480 individuals randomised, 78 067 to
enhanced reminder and 90 413 to the usual reminder.
Study approvals. Consent forms were not required in this study
because the interventions took place as part of individuals’ usual
communication from the BCSP.
Ethical Approval was obtained from the UK National Research
Ethics Service, London—Harrow Ethics Committee, Reference
number 12/LO/1396 prior to commencement of the study. Local
Ethics Committee approval was not required as this was a national
trial incorporated within the BCSP. Site approval was obtained at
each of the Bowel Cancer Screening Programme Hubs.
Patient involvement. Patient and third sector representatives
were involved in the planning and development of all four
interventions examined in the ASCEND trials and a bowel cancer
patient was a co-applicant on the study. The research team also
undertook patient and public engagement activities, presenting
information about the study at conferences and to other groups.
(Supplementary file 3).
RESULTS
The RCT included 168 480 individuals from 99 clusters.
Table 1 describes the characteristics of the study individuals by
trial arm. The arms were well balanced with respect to sex. For
other variables, there were slight imbalances between trial arms,
presumably induced by between-hub between-day differences in
individuals sent reminders. The proportion of individuals
decreased as deprivation increased in both arms. This is because
individuals were categorised by IMD quintiles based on the
national distribution of scores, rather than by the distribution of
scores in our sample (i.e., not 20% in each quintile). The enhanced
reminder arm was characterised by older individuals, a higher
proportion of prevalence screens in previous non-participants and
fewer first ever screening episodes.
Table 2 shows the percentages and absolute numbers adequately
screened by trial arm, stratified in turn by sex, age, screening
episode type, hub and IMD quintile. Overall, there was 0.7
percentage point higher participation rate with the enhanced
reminder (25.8% compared with 25.1% uptake after the usual
reminder). This was not significant in the univariate analysis, but
was significant when adjusted for age, sex, hub and screening
episode type (adjusted OR¼ 1.07, 95% CI 1.03–1.11, P¼ 0.001,
Table 3), from 25.1 to 25.8% uptake. In both trial arms and overall,
higher participation rates were observed for females, younger
individuals, incident screens (i.e., in persons who had previously
participated), the Southern hub and the less-deprived quintiles.
In terms of the relationship of this trial to the GPE trial, the
unadjusted OR for uptake associated with the enhanced reminder
in those not in the GPE trial was 1.06, higher than the overall
unadjusted OR of 1.04. Furthermore, the OR associated with
receiving the enhanced reminder adjusted for GPE trial status was
1.04, identical to the unadjusted OR.
There was a significant interaction between trial arm and IMD
quintile after adjustment (P¼ 0.005). Table 4 shows the adjusted
ORs from multivariate analysis stratified by IMD quintile. Within
the most deprived quintile, the odds of returning a completed kit
were 11% higher in the enhanced reminder arm (absolute increase
from 13.3 to 14.1%). There was no difference in the odds of
returning a completed kit within the least deprived quintile. Odds
ratios were similar across the three most deprived quintiles,
ranging from 1.09 to 1.13 and in each case were significantly higher
in the enhanced reminder group compared with the usual
reminder group.
Table 3 shows the multivariate adjusted effects of trial arm, sex,
age, screening episode type, hub and IMD quintile, with each factor
adjusted for all others in the logistic regression. The differences in
participation by trial arm, sex, screening episode type, hub and
IMD quintile were all statistically significant.
Table 5 gives the effect of the enhanced reminder within
subgroups of sex, age, hub and screening episode type, and the test
for interaction of the intervention with IMD quintile. The effect of
the enhanced reminder was stronger in the London and Northeast
hubs (although the effect was not significant), and the interaction
between trial arm and IMD quintile was strongest in the
Southern hub.
A 7% increase in the odds of screening across all individuals in
the adjusted model was associated with predictive margins
(adjusted average probabilities of uptake) of 0.259 (95% CI
0.255–0.265) in the enhanced reminder group and 0.250 (95% CI
0.248– 0.253) in the usual reminder group. This implies a 3.6%
relative increase in the probability of screening (0.259/0.250) and a
0.9 percentage point absolute increase (0.259–0.250; the average
marginal effect). The adjusted effect was larger than the unadjusted
(see discussion below). In the 2013/14 fiscal year the number of
reminder letters sent in the BCSP in England was 2 144 277.
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(BCSSN, 2015) An average marginal effect of 0.9 percentage points
(0.009) suggests that if the enhanced reminder were implemented
nationally, then 19 298 extra people each year might be screened.
In 2013/14 the positivity rate among the screened population was
1.84%. (BCSSN, 2015) Evidence suggests that 83% of people with a
positive test result attend a specialist screening practitioner clinic
and undergo further investigation, and among those who go on to
have further investigations, 10.1% will have a colorectal cancer and
27.2% will have colorectal adenomatous polyps classed as
intermediate or high risk requiring further investigation. (Logan
et al, 2012) Hence, if the enhanced reminder were implemented
nationally it might detect up to an additional 80 people
(19 298*0.0184*0.83*0.272) with polyps classed as high or inter-
mediate risk, and 30 people (19 298*0.0184*0.83*0.101) with a
colorectal cancer in England each year.
The enhanced reminder incurred a one-off cost of d78000 to
modify the usual reminder within the NHS BCSP. This would not
need to be incurred again if the enhanced reminder were
implemented. No additional costs were incurred per person invited
to screening, hence the average marginal cost per additional
enhanced reminder was zero.
DISCUSSION
The addition of simple, brief messages to the usual BCSP reminder
letter increased the odds of participation in the Programme by 11%
among those living in the most deprived areas (in absolute terms
from 13.3 to 14.1% uptake) and by 7% (from 25.1 to 25.8% uptake)
overall. As a result of our research design, whereby the intervention
was embedded within the BCSP’s usual practice, these benefits can
be realised immediately, with no operational changes required and
at no additional cost. We estimate the enhanced reminder can
result in up to 80 more people with high or intermediate risk
polyps and 30 additional colorectal cancers detected in England
each year. The stronger effect of the enhanced reminder in low
socioeconomic status groups is reflected in the corresponding
stronger effect suggested in London and the Northeast.
A major strength of our trial is its national coverage and the
large sample size yielding substantial statistical power to detect
small differences in uptake between subgroups. The trial was
specifically powered to detect socioeconomic differences in the
effect on uptake, allowing us to draw conclusions about
the demonstrated differences between IMD quintiles, but not
about the relevance of the other statistically significant differences
found. This is, to our knowledge the first trial specifically designed
to examine effects across the entire socioeconomic gradient and the
first intervention to result in a slightly greater proportional effect in
more deprived populations. Our results could be argued to satisfy
Victora’s ‘inverse equity’ hypothesis, which predicts that newly
implemented public health interventions initially reach those of
higher socioeconomic status and only later affect the poor when
the affluent have achieved new minimum achievable levels for
morbidity, a hypothesis that has been confirmed internationally.
(Victoria et al, 2000).
Until recently, studies that addressed socioeconomic inequalities
in uptake tended to focus specifically on under-served groups.
(Ahmed et al, 2010) Even if they are successful, these initiatives do
not benefit the larger population in need outside the targeted
group. In addition, they are often highly intensive (e.g., by
providing community support workers) and are therefore
impractical for wide-scale implementation. More recently less-
resource-intensive interventions such as text message reminders
Table 1. Distributions of the study population in each arm of the trial by sex, age, screening episode type, hub and IMD quintile
Usual reminder Enhanced reminder Total
Factor No. % No. % No. %
Sex
Male 46 839 51.8 40 320 51.7 87 159 51.7
Female 43 574 48.2 37 747 48.4 81 321 48.3
Age (years)a
o65 46771 51.7 38 390 49.2 85 161 50.6
65–69 27.781 30.7 24 870 31.9 52 651 31.2
70–74 15861 17.5 14 807 19.0 30 668 18.2
Screening episode type
Prevalent first time 21271 23.5 14 483 18.5 35 754 21.2
Incident 25 813 28.5 23 722 30.4 49 535 29.4
Prevalent previous non responder 43 329 47.9 39 862 51.1 83 191 49.4
Hub
Midlands and NorthWest 25 490 28.2 22 051 28.2 47 541 28.2
Southern 23 107 25.6 19 131 24.5 42 238 24.5
London 10385 11.5 10 809 13.8 21 194 13.8
North East 12 796 14.1 12 291 15.7 25 087 15.7
Eastern 18 635 20.6 13 785 17.7 32 420 17.7
IMD quintileb
1 (least deprived) 18 928 20.9 15 933 20.4 34 861 20.7
2 19446 21.5 16 594 21.3 36 040 21.4
3 18286 20.2 16 092 20.6 34 378 20.4
4 16853 18.6 14 679 18.8 31 532 18.7
5 (most deprived) 16 489 18.2 14 441 18.5 30 930 18.4
Not known 411 0.4 328 0.4 739 0.4
Total 90 413 78 067 168480
‘Prevalent first time’: people being invited for the first time. ‘Incident’: invitations to people who have participated in screening previously. ‘Prevalent previous non responder’: people invited to
be screened at least once previously, who have never responded.
aSome individuals were invited just before their 60th birthday
bIndex of multiple Deprivation: quintile based on national distributions using pre-defined national cut-offs.
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have been found to increase attendance at breast screening
appointments (Kerrison et al, 2015) and their effectiveness in
improving uptake of gFOBT screening in the BCSP is currently
being examined. (Hirst et al, 2015).
We were unable, for logistical reasons, to use individual
randomisation and this led us to implement cluster randomisation
as the strongest alternative. If anything, this led to an under-
estimation of the effect. This can be seen if one considers the
overall absolute difference in participation between the enhanced
and usual reminder arms (0.7%) along with the differences
observed within individual hubs, of 0.6% (Midlands and North-
west), 0.9% (Southern), 1.5% (London), 1.5% (Northeast) and 0.4%
(Eastern). The average of the latter, weighted by study population
in each hub is 0.9%, larger than the overall unadjusted effect. This
probably reflects a greater and more systematic variation between
clusters than was anticipated when the trial was designed. This is
also almost certainly the reason for a larger and more significant
multivariate adjusted effect than the unadjusted. Ideally, future
studies should be randomised at individual level, and if this is not
possible, stratified analyses, conditional on hub and possibly other
covariates should be planned a priori.
Although we used an area-based measure of deprivation, which
may underestimate individual effects, IMD quintile has been
demonstrated ability to explain socioeconomic variations in bowel
cancer screening uptake at the LSOA level. (von Wagner et al,
2011) IMD is widely used, enabling direct comparison of our
results with other studies.
There may have been some individuals who received the usual
or enhanced reminder after sending in a kit. This would have the
tendency to underestimate the effect of the enhanced reminder.
It is also worth noting that the enhanced reminder arm of the study
had older individuals and a greater proportion of prevalent
screening invitations. These would be likely to attenuate the effect
of the enhanced reminder because the enhanced reminder arm
Table 2. Numbers and percentages of individuals adequately screened, by trial arm and sex, age, screening episode type, hub
and IMD quintile
Number (%) adequately screened
Factor Usual reminder Enhanced reminder Total
Sex
Male 11 201 (23.9) 9 899 (24.6) 21 100 (24.2)
Female 11 511 (26.4) 10 267 (27.2) 21 778 (26.8)
Age
o65 12 229 (26.1) 10 251 (26.7) 22 480 (26.4)
65–69 6898 (24.8) 6674 (26.8) 13 572 (25.8)
70–74 3585 (22.6) 3241 (21.9) 6826 (22.3)
Screening episode type
Prevalent first time 5398 (25.4) 3739 (25.8) 9137 (25.6)
Incident 14 985 (58.0) 14 033(59.2) 29 018 (58.6)
Prevalent previous non responder 2329 (5.4) 2394 (6.0) 4723 (5.7)
Hub
Midlands and North-West 5899 (23.1) 5231 (23.7) 11 130 (23.4)
Southern 6795 (29.4) 5827 (30.5) 12 622 (29.9)
London 2196 (21.1) 2444 (22.6) 4640 (21.9)
North East 2836 (22.2) 2911 (23.7) 5747 (22.9)
Eastern 4986 (26.8) 3753 (27.2) 8739 (27.0)
IMD quintile
1 (least deprived) 6601 (34.9) 5522 (34.7) 12 123(34.8)
2 5782 (29.7) 5107 (30.8) 10 889 (30.2)
3 4578 (25.0) 4316 (26.8) 8894 (25.9)
4 3436 (20.4) 3104 (21.1) 6540 (20.7)
5 (most deprived) 2198 (13.3) 2040 (14.1) 4238 (13.7)
Total 22 712 (25.1) 20 166 (25.8) 42 878 (25.4)
Table 3. Adjusted odds ratios and 95% confidence intervals
or the effect of each variable on participation
Mulitivariate logistic regression
resultsa
Factor Odds ratio (95%CI) P-value
Trial arm
Usual reminder 1.00
Enhanced reminder 1.07 (1.03–1.11) Po0.001
Screening episode type
Prevalent first time 1.00
Incident 4.55 (4.39–4.71) Po0.001
Prevalent previous non responder 0.20 (0.19–0.21) Po0.001
Sex
Male 1.0
Female 1.03 (1.00–1.06) P¼ 0.024
Age
59–64 1.0
65–69 0.85 (0.82–0.88) Po0.001
70–74 0.66 (0.64–0.68) Po0.001
Hub
Midlands and NorthWest 1.00
Southern 1.03 (0.99–1.08) P¼ 0.123
London 0.88 (0.83–0.93) Po0.001
NorthEast 0.96 (0.91–1.00) P¼ 0.062
Eastern 0.98 (0.92–1.04) P¼ 0.451
IMD quintile
1 (least deprived) 1.00
2 0.84 (0.81–0.88) Po0.001
3 0.71 (0.68–0.74) Po0.001
4 0.58 (0.55–0.61) Po0.001
5 (most deprived) 0.38 (0.36–0.40) Po0.001
aAdjusted for sex, age, screening episode type, IMD quintile, trial arm and hub.
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contained a higher proportion of previous non-responders who are
much less likely to respond to a screening invitation compared
with first timers and people who have already participated in a
previous round. (Steele et al, 2010; Lo et al, 2015) As can be seen
from Table 2, the previous non-responders had an overall
participation rate of 6% compared with 59% in previous
responders. Thus the true increase in participation with the
enhanced reminder is likely to be greater than reported here.
We used published data from 2013/14 to estimate the additional
number of colorectal cancers and high or intermediate risk polyps
detected annually by implementing the enhanced reminder. These
figures vary between geographical regions and change over time.
For example, in common with all successful population screening
programmes, the proportion of cases identified by the Programme
falls as the proportion of individuals in the population who have
been repeatedly screened increases.
Contamination between study groups could have occurred if, for
example, household members were randomised to different arms
of the trial during the 4-week study period. Although this
limitation is noted, it would also have applied to a parallel
randomised trial. It is also possible that concurrent initiatives
affected uptake. We therefore surveyed the number and location of
interventions occurring during the four national trials (of which
enhanced reminder was one) and identified nine research studies
and 27 health promotion activities focusing on bowel cancer
screening occurring within the time frame of the trials. However, it
is unlikely that they influenced our results because the chance of
these initiatives occurring on the same alternate days as enhanced
reminder would be negligible.
In conclusion, this large national trial demonstrated that a
simple, brief message to enhance awareness of bowel cancer and
clarify the objective of cancer screening, disseminated as part of
routine practice by the BCSP, achieved a greater proportional effect
in more deprived populations. This enhanced reminder incurred a
small cost to implement and will incur only minimal maintenance
costs if rolled out into routine practice. It could identify 80 more
individuals with high or intermediate risk polyps and 30 additional
bowel cancers in England each year.
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Variable OR (95% CI), enhanced vs usual reminder, Significance of effect Significance of interactiona
Sex
Male 1.04 (0.95–1.14) P¼0.41 P¼0.37
Female 1.04 (0.95–1.13) P¼0.45 P¼0.24
Age
o65 1.03 (0.96–1.11) P¼0.44 P¼0.06
65–69 1.11 (0.99–1.25) P¼0.08 P¼0.62
70–74 0.96 (0.83–1.10) P¼0.56 P¼0.79
Hub
Midlands and NorthWest 1.03 (0.96–1.11) P¼0.38 P¼0.99
Southern 1.05 (0.92–1.20) P¼0.44 P¼0.001
London 1.09 (0.93–1.28) P¼0.29 P¼0.90
NorthEast 1.09 (0.97–1.22) P¼0.14 P¼0.73
Eastern 1.02 (0.84–1.25) P¼0.81 P¼0.98
Screening episode type
Prevalent first time 1.02 (0.95–1.10) P¼0.51 P¼0.12
Incident 1.05 (0.97–1.12) P¼0.21 P¼0.05
Prevalent previous non responder 1.12 (1.03–1.23) P¼0.008 P¼0.43
aP-value for heterogeneity of effect of enhanced reminder by IMD expressed as a continuous score within each subgroup.
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